KR20170132318A - 인지 저하의 위험을 예측하는 방법 - Google Patents

인지 저하의 위험을 예측하는 방법 Download PDF

Info

Publication number
KR20170132318A
KR20170132318A KR1020177031704A KR20177031704A KR20170132318A KR 20170132318 A KR20170132318 A KR 20170132318A KR 1020177031704 A KR1020177031704 A KR 1020177031704A KR 20177031704 A KR20177031704 A KR 20177031704A KR 20170132318 A KR20170132318 A KR 20170132318A
Authority
KR
South Korea
Prior art keywords
level
ferritin
patient
csf
apoe
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020177031704A
Other languages
English (en)
Korean (ko)
Inventor
스콧 애이튼
노엘 폭스
애슐리 이안 부쉬
Original Assignee
씨알씨 포 멘탈 헬스 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2015901210A external-priority patent/AU2015901210A0/en
Application filed by 씨알씨 포 멘탈 헬스 리미티드 filed Critical 씨알씨 포 멘탈 헬스 리미티드
Publication of KR20170132318A publication Critical patent/KR20170132318A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/84—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving inorganic compounds or pH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/0048—Detecting, measuring or recording by applying mechanical forces or stimuli
    • A61B5/0055—Detecting, measuring or recording by applying mechanical forces or stimuli by applying suction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/05—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves
    • A61B5/055—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue
    • A61B5/14507—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue specially adapted for measuring characteristics of body fluids other than blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/40—Detecting, measuring or recording for evaluating the nervous system
    • A61B5/4058—Detecting, measuring or recording for evaluating the nervous system for evaluating the central nervous system
    • A61B5/4064—Evaluating the brain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/40—Detecting, measuring or recording for evaluating the nervous system
    • A61B5/4076—Diagnosing or monitoring particular conditions of the nervous system
    • A61B5/4088—Diagnosing of monitoring cognitive diseases, e.g. Alzheimer, prion diseases or dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A61B5/4842—Monitoring progression or stage of a disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/72—Signal processing specially adapted for physiological signals or for diagnostic purposes
    • A61B5/7271—Specific aspects of physiological measurement analysis
    • A61B5/7275—Determining trends in physiological measurement data; Predicting development of a medical condition based on physiological measurements, e.g. determining a risk factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/775—Apolipopeptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medical Informatics (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Analytical Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Physiology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Psychology (AREA)
  • Genetics & Genomics (AREA)
KR1020177031704A 2015-04-02 2016-04-01 인지 저하의 위험을 예측하는 방법 Withdrawn KR20170132318A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
AU2015901210 2015-04-02
AU2015901210A AU2015901210A0 (en) 2015-04-02 Method for predicting risk of cognitive deterioration
AU2016900347A AU2016900347A0 (en) 2016-02-03 Method for predicting risk of cognitive deterioration
AU2016900347 2016-02-03
PCT/AU2016/050248 WO2016154682A1 (en) 2015-04-02 2016-04-01 Method for predicting risk of cognitive deterioration

Publications (1)

Publication Number Publication Date
KR20170132318A true KR20170132318A (ko) 2017-12-01

Family

ID=57003726

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020177031704A Withdrawn KR20170132318A (ko) 2015-04-02 2016-04-01 인지 저하의 위험을 예측하는 방법

Country Status (9)

Country Link
US (1) US20180284141A1 (cg-RX-API-DMAC7.html)
EP (1) EP3278113A4 (cg-RX-API-DMAC7.html)
JP (1) JP2018513368A (cg-RX-API-DMAC7.html)
KR (1) KR20170132318A (cg-RX-API-DMAC7.html)
CN (1) CN107636468A (cg-RX-API-DMAC7.html)
AU (1) AU2016240409A1 (cg-RX-API-DMAC7.html)
BR (1) BR112017021098A2 (cg-RX-API-DMAC7.html)
CA (1) CA2981533A1 (cg-RX-API-DMAC7.html)
WO (1) WO2016154682A1 (cg-RX-API-DMAC7.html)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102406900B1 (ko) 2021-08-19 2022-06-08 의료법인 명지의료재단 노인 상태 개선 방법 및 시스템
KR20230111921A (ko) * 2022-01-19 2023-07-26 이화여자대학교 산학협력단 뇌연령에 기초한 연령 관련 인지 저하 모니터링 방법 및 장치
KR20240009795A (ko) * 2022-07-14 2024-01-23 이화여자대학교 산학협력단 뇌영상으로부터 뇌성별 및 뇌연령을 예측하는 방법 및 장치

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10969453B2 (en) * 2016-01-22 2021-04-06 Synaptive Medical Inc. Systems and methods for magnetic field-dependent relaxometry using magnetic resonance imaging
WO2018064715A1 (en) * 2016-10-03 2018-04-12 Crc For Mental Health Ltd Method for predicting or diagnosing cognitive deterioration
EP3531915B1 (en) 2016-10-24 2024-12-04 Akili Interactive Labs, Inc. Cognitive platform configured as a biomarker or other type of marker
JP6849975B2 (ja) * 2016-11-02 2021-03-31 国立大学法人九州大学 アルツハイマー病のリスクの決定方法
CN110603550A (zh) * 2016-12-13 2019-12-20 阿克利互动实验室公司 利用导航任务识别生物标志物和利用导航任务进行治疗的平台
WO2018148788A1 (en) * 2017-02-17 2018-08-23 Crc For Mental Health Ltd Method for predicting risk and rate of amyloid deposition and plaque formation
WO2018176082A1 (en) * 2017-03-28 2018-10-04 Crc For Mental Health Ltd Predicting progression of cognitive deterioration
JP6199520B1 (ja) * 2017-04-11 2017-09-20 株式会社アルム 保険管理装置、および保険管理システム
US11234657B2 (en) * 2017-05-01 2022-02-01 Rhode Island Hospital Non-invasive measurement to predict post-surgery anterior cruciate ligament success
KR102076091B1 (ko) * 2017-08-30 2020-02-11 사회복지법인 삼성생명공익재단 기억성 경도인지장애(aMCI) 환자에 대한 아밀로이드 페트 검사 양성률 예측 방법 및 장치
EP3861352A4 (en) * 2018-10-04 2022-08-03 University of Manitoba NOVEL BIOMARKER FOR HUMAN ALZHEIMER'S DISEASE
CN109464122B (zh) * 2018-11-05 2022-02-18 西南大学 基于多模态数据的个体核心特质预测系统及方法
WO2020261608A1 (ja) * 2019-06-28 2020-12-30 株式会社島津製作所 アミロイドβの脳内蓄積状態評価方法及び評価装置
CA3151632A1 (en) * 2019-08-20 2021-02-25 Terran Biosciences, Inc. Neuromelanin-sensitive mri for assessing parkinson's disease
WO2021039941A1 (ja) * 2019-08-30 2021-03-04 ニプロ株式会社 アルツハイマー型認知症又は軽度認知症を判別する方法
US11798652B2 (en) 2020-08-24 2023-10-24 Kpn Innovations, Llc. Method of and system for identifying and ameliorating body degradations
US11416776B2 (en) 2020-08-24 2022-08-16 Kpn Innovations, Llc. Method of and system for identifying and enumerating cross-body degradations
US11179110B1 (en) 2020-08-31 2021-11-23 Kpn Innovations Llc Method of system for reversing inflammation in a user
CN112526132A (zh) * 2020-11-23 2021-03-19 华中科技大学 预测2型糖尿病患者出现记忆力衰退的风险的方法
CN112353381B (zh) * 2020-11-24 2022-06-28 杭州冉曼智能科技有限公司 基于多模态大脑影像的阿尔茨海默症综合诊断系统
CN114724709B (zh) * 2022-06-07 2022-10-14 深圳市铱硙医疗科技有限公司 基于vr眼动追踪的痴呆风险筛查系统、设备及介质
CN120089387B (zh) * 2025-05-07 2025-07-15 脑玺(苏州)智能科技有限公司 超早期认知下降状态的识别方法、装置及电子设备

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001279515A1 (en) * 2000-07-25 2002-02-05 Hyman M. Schipper Ho-1 suppressor as a diagnostic and prognostic test for dementing diseases
CN100535004C (zh) * 2000-08-04 2009-09-02 洛马林达大学医学中心 用作神经变性疾病诊断的铁调节蛋白-2
AU2003251920A1 (en) * 2002-07-12 2004-02-02 The Buck Institute For Research On Aging Iron sequestration or elimination to reduce neurodegeneration or parkinsons disease progression
US20040102692A1 (en) * 2002-11-27 2004-05-27 General Electric Company Magnetic resonance imaging system and methods for the detection of brain iron deposits
US20050020904A1 (en) * 2003-07-10 2005-01-27 Cline Harvey Ellis System and method for the detection of brain iron using magnetic resonance imaging
US7728038B2 (en) * 2004-08-04 2010-06-01 University Of Utah Research Foundation Methods for chelation therapy
US20110236917A1 (en) * 2009-11-17 2011-09-29 Power3 Medical Products, Inc. Diagnosis of Alzheimer's Disease
WO2012027794A2 (en) * 2010-09-01 2012-03-08 The Mental Health Research Institute Of Victoria Method of treatment and agents useful for same
CN102743365A (zh) * 2011-04-19 2012-10-24 辽宁省计划生育科学研究院 一种化合物或其药学上可接受的盐在防治老年痴呆的应用
AU2012304646B2 (en) * 2011-09-06 2017-02-23 University Of Florida Research Foundation, Inc. Systems and methods for detecting the presence of anomalous material within tissue
CN103251932A (zh) * 2013-04-17 2013-08-21 钱忠明 铁调素在制备铁相关神经退行性疾病药物中的应用

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102406900B1 (ko) 2021-08-19 2022-06-08 의료법인 명지의료재단 노인 상태 개선 방법 및 시스템
KR20230111921A (ko) * 2022-01-19 2023-07-26 이화여자대학교 산학협력단 뇌연령에 기초한 연령 관련 인지 저하 모니터링 방법 및 장치
KR20240009795A (ko) * 2022-07-14 2024-01-23 이화여자대학교 산학협력단 뇌영상으로부터 뇌성별 및 뇌연령을 예측하는 방법 및 장치

Also Published As

Publication number Publication date
JP2018513368A (ja) 2018-05-24
EP3278113A1 (en) 2018-02-07
WO2016154682A1 (en) 2016-10-06
AU2016240409A1 (en) 2017-11-09
BR112017021098A2 (pt) 2018-07-03
US20180284141A1 (en) 2018-10-04
CA2981533A1 (en) 2016-10-06
EP3278113A4 (en) 2018-11-21
CN107636468A (zh) 2018-01-26

Similar Documents

Publication Publication Date Title
KR20170132318A (ko) 인지 저하의 위험을 예측하는 방법
Alirezaei et al. Neurofilament light chain as a biomarker, and correlation with magnetic resonance imaging in diagnosis of CNS-related disorders
Nation et al. Blood–brain barrier breakdown is an early biomarker of human cognitive dysfunction
Arenaza-Urquijo et al. The metabolic brain signature of cognitive resilience in the 80+: beyond Alzheimer pathologies
Popp et al. Cerebrospinal fluid cortisol and clinical disease progression in MCI and dementia of Alzheimer's type
Howell et al. Race modifies the relationship between cognition and Alzheimer’s disease cerebrospinal fluid biomarkers
Burnham et al. A blood-based predictor for neocortical Aβ burden in Alzheimer’s disease: results from the AIBL study
US12345717B2 (en) Biomarkers and methods relating to Alzheimer's disease
Gupta et al. Plasma apolipoprotein J as a potential biomarker for Alzheimer's disease: Australian Imaging, Biomarkers and Lifestyle study of aging
CA2877975C (en) Specific salivary biomarkers for risk detection, early diagnosis, prognosis and monitoring of alzheimer's and parkinson's diseases
Wang et al. Cerebrospinal fluid levels of YKL-40 in prodromal Alzheimer’s disease
US20130116135A1 (en) Methods, Kits and Reagents for Diagnosing, Alding Diagnosis and/or Monitoring Progression of a Neurological Disorder
KR20230010687A (ko) 알츠하이머 병 평가용 단백질 마커
EP4252243A2 (en) Non-invasive assessment of alzheimer's disease
Zecca et al. Plasma β-amyloid1–42 reference values in cognitively normal subjects
Fei et al. The relationship of plasma Aβ levels to dementia in aging individuals with mild cognitive impairment
Henchcliffe et al. Biomarkers of Parkinson's disease and Dementia with Lewy bodies
Gawor et al. Amygdala-predominant α-synuclein pathology is associated with exacerbated hippocampal neuron loss in Alzheimer’s disease
Lu et al. Cerebrospinal fluid growth-associated protein 43 levels in patients with progressive and stable mild cognitive impairment
US20120295281A1 (en) Specific salivary biomarkers for risk detection, early diagnosis, prognosis and monitoring of alzheimer's and parkinson's diseases
Novarella et al. Neurofilament light chain and Alzheimer pathology biomarkers in elderly people with multiple sclerosis
WO2018148788A1 (en) Method for predicting risk and rate of amyloid deposition and plaque formation
Menne et al. Diagnose it yourself: will there be a home test kit for Alzheimer’s disease?
Yan et al. Serum p‐tau217 Is a Prognostic Indicator of Cognitive Impairment in Idiopathic REM Sleep Behavior Disorder
HK40083580A (en) Protein markers for assessing alzheimer's disease

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20171101

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination